Ianalumab Meets Primary End Points in Phase 3 NEPTUNUS Trials of Sjögren’s Disease
Written by
Neurology Live
Published
0
comments
0
min
Novartis revealed promising phase 3 trial results for ianalumab, a potential first treatment for Sjögren’s disease, showing significant disease activity reduction.